Predictors of Psoriasis Area and Severity Index 100 response in Korean patients with moderate-to-severe plaque psoriasis receiving biologics
- By Tae-Rim Kim,
- Yumi Won,
- Yeona Kim,
- Sang-Hyeon Won,
- Kyung-Nam Bae,
- Jungsoo Lee,
- Kihyuk Shin,
- Hoonsoo Kim,
- Hyunchang Ko,
- Moon-Bum Kim
- and Byungsoo Kim
Pages 518 to 523
Cite this article
- KIM, Tae-Rim,
- WON, Yumi,
- KIM, Yeona,
- WON, Sang-Hyeon,
- BAE, Kyung-Nam,
- LEE, Jungsoo,
- SHIN, Kihyuk,
- KIM, Hoonsoo,
- KO, Hyunchang,
- KIM, Moon-Bum
- and KIM, Byungsoo,
- Kim, Tae-Rim.,
- et al.
- Kim, T.-R.,
- Won, Y.,
- Kim, Y.,
- Won, S.-H.,
- Bae, K.-N.,
- Lee, J.,
- Shin, K.,
- Kim, H.,
- Ko, H.,
- Kim, M.-B.
- and Kim, B.
https://doi.org/10.1684/ejd.2023.4555
Cite this article
- Kim, T.-R.,
- Won, Y.,
- Kim, Y.,
- Won, S.-H.,
- Bae, K.-N.,
- Lee, J.,
- Shin, K.,
- Kim, H.,
- Ko, H.,
- Kim, M.-B.
- and Kim, B.
- Kim, Tae-Rim.,
- et al.
- KIM, Tae-Rim,
- WON, Yumi,
- KIM, Yeona,
- WON, Sang-Hyeon,
- BAE, Kyung-Nam,
- LEE, Jungsoo,
- SHIN, Kihyuk,
- KIM, Hoonsoo,
- KO, Hyunchang,
- KIM, Moon-Bum
- and KIM, Byungsoo,
https://doi.org/10.1684/ejd.2023.4555
Psoriasis is a chronic inflammatory skin disease clinically characterized by erythematous scaly plaques. It affects 1-3% of the world’s population [1], with an annual prevalence of 453 per 100,000 in Korea [2]. Patients with psoriasis often have high blood pressure, diabetes, and obesity compared with the general population, and these comorbidities occur more frequently as the severity of psoriasis increases [3, 4]. Psoriasis and its comorbidities can negatively affect a patient’s life physically and mentally [5].
There are various treatment modalities for psoriasis, including topical therapy, phototherapy, systemic non- biological therapies, and biological agents. Depending on the disease severity, response to previous treatments, quality of life issues, and comorbidities, different treatment modalities may be administered [6]. Approximately 20% of patients with psoriasis have moderate-to-severe psoriasis [7], wherein a biological agent can be used as monotherapy or combined therapy [8].
Several clinical trials involving different biological agents have shown remarkable safety and efficacy [9–12] and have ushered physicians into a new era in treating psoriasis. Achieving a Psoriasis Area and Severity Index (PASI) 100 response is important for improving the patient’s quality of life and the therapeutic perspective [13]. Reportedly, 46–58% of patients achieve PASI 100 at 48–52 weeks [9–12], and Asians show a relatively low PASI 100 response compared with non-Asians [14]…
Publisher keywords: biological agent, PASI 100, psoriasis
Uploaded: 09/23/2024
https://doi.org/10.1684/ejd.2023.4555This article is available in conditional access
Buy this article
€25.00